Safety Issues Not Dampening AbbVie Optimism For Humira Successors

AbbVie is optimistic that its JAK1 inhibitor upadacitinib and anti-IL23 candidate risankizumab can increase its autoimmune market share, doubting a thromboembolic class effect for JAK inhibitors.